All In Biotech

Drug Trial Radar · NCT07647614

A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets in Combination With Standard of Care for Treating Subjects With Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jan 1, 2030

Study completion Jan 1, 2030

Sponsor

Sponsor type
Industry
First posted
Jun 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is: Does ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment? Investigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no drug), to see if ENERGI-F705 Tablets work to treat Parkinson's disease. Participants will: * Take the study drugs twice a day for 72 weeks in the treatment group * Take routine use of standard-of-care antiparkinsonian medications throughout the study * Visit the outpatient department at scheduled visits, ranging from Day 1 to approximately every 1 to 4 weeks thereafter, for checkups and tests

Conditions

  • Parkinson's Disease (PD)

Interventions

  • 60 milligrams of ENERGI-F705 TabletsDrug

    Tablets will be taken orally twice a day

  • Placebo tabletsDrug

    Tablets will be taken orally twice a day.

  • 120 milligrams of ENERGI-F705 TabletsDrug

    Tablets will be taken orally twice a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants experiencing adverse events (AE) and serious adverse events (SAE)Time frame: From Day 1 to Week 76

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Neurology, Shuang Ho Hospital

    New Taipei City, Taiwan

  • Taipei Medical University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.